New pill shows promise for severe eczema sufferers
Disease control
Ongoing
This study tests an oral medication called KT-621 for people aged 12 to 75 with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and affected body area compared to a placebo. The trial lasts 16 weeks with a follow-up open-labe…
Phase: PHASE2 • Sponsor: Kymera Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC